arrow_back Back Filing freshness 10-Q Q1 FY2027 SEC EDGAR

Vistagen Therapeutics, Inc.

VTGN
$0.36 ▲ +0.11 (+41.16%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
78 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
13
Health
Poor
Bearish
auto_awesome

Analytical Summary

Vistagen Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $15.5M
Dividend Yield —
Revenue Growth 504.9%
Op. Margin None
ROIC -54.5% ↘
FCF / Share $-0.34
Trailing P/E —
Price / Book 0.6x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

78-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.48M
↑ +504.9% —
Net Income Profit after all expenses
$-13.03M
↑ +13.7% —
Operating Margin Operating profit as % of sales
-211.0%
↑ +34.4% —
FCF / Share Free cash flow per share
$-0.34
↑ +42.0% —
Long-Term Debt Long-term obligations
$0.00
— —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
3
Financial Health ↓
2
Cash Quality →
58

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 28 years · 78 quarters